

The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias: Response to the Cochrane editors

Table 1: Our reassessment of the studies we had identified as additionally eligible for the Cochrane HPV vaccine review

[*Key: RCT = randomised clinical trial]

N	Assessment	Funder	Study ID	NCT ID	Type of study	Clinical study report available on trial register	Number of females	Note
1	Eligible for inclusion in the Cochrane review	GSK	HPV-003	Not identified	RCT*	Yes: https://www.gsk-clinicalstudyregister.com/study/580299/003?search=study&csr	61	HPV-003 is listed in the Cochrane review as "not published"; however, HPV-003's clinical study report can be freely downloaded from GlaxoSmithKline's trial register. The Cochrane review include data from GlaxoSmithKline's trial register, so it could also include HPV-003.
2	Eligible for inclusion in the Cochrane review	GSK	HPV-040	NCT00534638	RCT	Yes: https://www.gsk-clinicalstudyregister.com/files2/gsk-106636-clinical-study-report-redact.pdf	20,515	HPV-040 was excluded from the Cochrane review, as it was considered a "phase IV" study (the Cochrane review only included phase II and III studies). We included HPV-040 in our list, as it is described as a "phase III/IV" study in the freely available clinical study report from GlaxoSmithKline's trial register. HPV-040 includes the bulk of the additional eligible participants: 32,176 of which 20,515 were females.
3	Eligible for inclusion in the Cochrane review	GSK	HPV-073	NCT01627561	RCT	No	148	HPV-073 was identified and added to the Cochrane review in the Cochrane editors' reassessment (1).
4	Eligible for inclusion in the Cochrane review	Merck	V501-018	NCT00092547	RCT	No	939	V501-018 had been excluded from the Cochrane review, as gender-specific data could not be obtained. However, the gender-specific data are available and can be obtained from EMA. It is unfortunate that these data were not obtained, as V501-018 is the only Gardasil study with a non-aluminium-containing comparator: "carrier solution" (yeast protein, sodium chloride, L-histidine, polysorbate 80 and sodium borate).
5	Eligible for inclusion in the Cochrane review	Merck	V501-028	NCT00411749	RCT	No	107	V501-028 was identified and added to the Cochrane review in the Cochrane editors' reassessment (1).
6	Eligible for inclusion in the Cochrane review	Merck	V501-030	NCT00496626	RCT	No	400	V501-030 had been excluded from the Cochrane review, as gender-specific data could not be obtained. However, the gender-specific data are available and can be obtained from EMA.
7	Eligible for inclusion in the Cochrane review	Merck	V501-046	NCT01245764	RCT	No	250	V501-046 was identified and added to the Cochrane review in the Cochrane editors' reassessment (1).
8	Eligible for inclusion in the Cochrane review	Merck	V503-006	NCT01047345	RCT	No	924	V503-006 was identified and added to the Cochrane review in the Cochrane editors' reassessment (1). The Cochrane review stated that it "did not include the nine-valent vaccine [Gardasil 9] ... since the randomised trials ... did not incorporate an arm with a non-HPV vaccine control" (3), but as we wrote "The only saline

